A protease activation mutant, MVCES1, as a safe and potent live vaccine derived from currently prevailing Sendai virus.
Sendai virus fresh isolates were shown to be antigenically different from the prototype Fushimi strain that had long been passaged in embryonated chicken eggs. Phylogenetic analysis of the hemagglutinin-neuraminidase genes also revealed the difference between these two virus groups. Both trypsin-resistant and elastase-sensitive mutations were additionally introduced to an LLC-MK2-cell-adapted and attenuated mutant derived from one of the fresh isolates. This protease activation mutant (MVCES1) showed the same antigenicity as the fresh isolates, and as a result of a single cycle of growth in lungs, it could confer better protection on mice against challenge infection with the currently prevailing Sendai virus than TR-5, which is a trypsin-resistant mutant derived from the Fushimi strain. The eligibility of MVCES1 as an attenuated live vaccine of Sendai virus is discussed.
Wang
X L
XL
Department of Microbiology, Kobe University School of Medicine, Japan.
Itoh
M
M
Hotta
H
H
Homma
M
M
D000595:Amino Acid Sequence; D000818:Animals; D010450:Endopeptidases / Q000494:pharmacology; D006389:Hemagglutinins, Viral / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D009154:Mutation; D010222:Parainfluenza Virus 1, Human / Q000187:drug effects / Q000235:genetics* / Q000276:immunology; D018184:Paramyxoviridae Infections / Q000517:prevention & control*; D012449:Safety; D017386:Sequence Homology, Amino Acid; D014611:Vaccination; D014613:Vaccines, Attenuated; D014760:Viral Fusion Proteins / Q000187:drug effects / Q000235:genetics; D014765:Viral Vaccines
D006389:Hemagglutinins, Viral; D014613:Vaccines, Attenuated; D014760:Viral Fusion Proteins; D014765:Viral Vaccines; D010450:Endopeptidases